Florida Hospital

Joining forces with the International Prostate Cancer Foundation to develop better tests

by Patrick Bartosch on May 17, 2013 at 6:01 am | 1 comment

Drs. Perera (left) and Patel during the "A Celebration of Collaboration" ceremony on May 10

During a ceremony at Sanford-Burnham at Lake Nona on May 10, the International Prostate Cancer Foundation (IPCF) awarded Ranjan Perera, Ph.D., scientific director of analytical genomics and bioinformatics at our Lake Nona campus, $60,000 to fund a postdoctoral fellow in Dr. Perera’s lab.

“Sanford-Burnham can really make an impact in the field,” said Vipul Patel, M.D., FACS, founder of the IPCF and internationally renowned prostate cancer surgeon at Florida Hospital’s Global Robotics Institute, as he acknowledged Dr. Perera’s work to identify molecular markers for prostate cancer. Given IPCF and Sanford-Burnham’s shared goal to develop better diagnoses and treatments, this postdoc grant will hopefully only be a first step in a long and mutually beneficial partnership.

Partnering with Asia’s largest pharmaceutical company to find obesity treatments

by Patrick Bartosch on February 11, 2013 at 11:00 pm | 0 Comments

Full Article

Drs. Smith (TRI), Izumo (Takeda), and Kelly (Sanford-Burnham; left to right) in traditional Japanese coats at the signing ceremony for the renewed partnership

We held a special signing ceremony today at our Lake Nona, Orlando, campus to renew our research agreement with Florida Hospital and Takeda Pharmaceutical Company Limited. The renewal extends our collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline. We and our partners expect this model will shorten the time to develop new therapeutics.

Interest in the development of obesity treatments remains strong, as the regulatory approval of two new obesity therapeutics in 2012 offered a proven pathway for drug candidates. “As the worldwide obesity crisis continues to escalate, we are seeing a rise in the prevalence of severe obesity—defined by BMI greater than 40—and we know that this subset of the obese population experiences increased mortality and associated diseases, such as heart disease, diabetes and cancer,” said Steven R. Smith, M.D., scientific director of the Florida Hospital – Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI) and president-elect of The Obesity Society. “These statistics are staggering and clearly demonstrate the need to rapidly develop treatment strategies for obesity.”

How belly fat differs from thigh fat—and why it matters

by Heather Buschman, Ph.D. on January 9, 2013 at 6:20 am | 4 Comments

Full Article

Researchers discover that the genes active in a person’s belly fat are significantly different from those in his or her thigh fat, a finding that could shift the way we approach unwanted belly fat—from banishing it to relocating it.

Men tend to store fat in the abdominal area, but don’t usually have much in the way of hips or thighs. Women, on the other hand, are more often pear-shaped—storing more fat on their hips and thighs than in the belly.

Why are women and men shaped differently?

The answer still isn’t clear, but it’s an issue worth investigating, says Steven Smith, M.D., director of the Florida Hospital – Sanford-Burnham Translational Research Institute for Metabolism and Diabetes. That’s because belly fat is associated with higher risks of heart disease and diabetes. On the other hand, hip and thigh fat don’t seem to play a special role in these conditions.

Translational Research Institute establishes new research paradigm for metabolic diseases

Originally published March 27, 2012

Florida Hospital and Sanford-Burnham today celebrate the opening of the Florida Hospital – Sanford-Burnham Translational Research Institute for Metabolism and Diabetes’ (TRI) new state-of-the-art facility in downtown Orlando, Fla., dedicated to the advancement of a new paradigm of personalized approaches to researching and treating diabetes and obesity.

“We are witnessing the rise of personalized medicine, most notably in cancer. Our goal at the TRI is to accelerate the advancement of personalized medicine in diabetes and obesity,” said Steven Smith, M.D., Sanford-Burnham professor and scientific director of the TRI. “We are working to rapidly expand knowledge of complex genetic and molecular causes of diabetes and obesity so that we can better define disease subpopulations. By working independently and in partnership with industry, we hope to develop therapies and treatment approaches tailored to those subpopulations. Our ultimate goal is that our discoveries will someday lead to cures for certain patients.”

A “twisted” grand opening ceremony

by Patrick Bartosch on March 29, 2012 at 3:35 pm | 0 Comments

Full Article

TRI grand opening speakers (from left to right): John Reed, Terry Owen, Dan Kelly, Steve Smith, Lars Houmann, Des Cummings, Don Jernigan

“My goal is to cure diabetes,” Steven Smith, M.D., scientific director of the Florida Hospital – Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI), said boldly at the opening ceremony of the TRI’s new state-of-the-art facility in downtown Orlando on March 27. “We believe that personalized medicine is our best shot at discovering cures for our most serious health problems like diabetes.”

The ceremony’s highlight was the unveiling of a spectacular nine-foot double-helix DNA structure that will be placed at the main entrance of the building, symbolizing the fundamental research being conducted at the TRI, as well as the synergies and collaborations the TRI represents. Selected board members and presenters each added one illuminated “bar,” representing a nucleotide, to the double helix.

“This is one of those rare times when the reality far exceeds the dream,” said John Reed, M.D., Ph.D., CEO of Sanford-Burnham. “The TRI is a wonderful opportunity for our organization, which will bring more and more to life our slogan From Research, the Power to Cure. We’re very excited about this opportunity to take our relationship with Florida Hospital to the next level.”

Translational Research Institute establishes new research paradigm for metabolic diseases

by Patrick Bartosch on March 27, 2012 at 6:00 am | 0 Comments

Full Article

New TRI Facility in Downtown Orlando

Introducing the Partnership for Personalized Medicine in Florida

by Deborah Robison on February 8, 2012 at 6:01 am | 0 Comments

Full Article

Sanford-Burnham, Moffitt and Florida Hospital form Personalized Medicine Partnership of Florida

Sanford-Burnham, Moffitt Cancer Center, and Florida Hospital announced today that they will collaborate to create a Personalized Medicine Partnership of Florida (PMP Florida). The partnership will conduct research to speed up discovery and develop new treatments in the areas of cancer and metabolic diseases, including obesity, diabetes, and cardiovascular disease.

The organizations will utilize new molecular and genomic technologies to discover, translate, and personalize interventions for preventing and treating diseases more efficiently to improve outcomes, while reducing costs. The partnership will speed up the discovery and development of new treatments by bringing together the complementary strengths of Florida Hospital’s large patient population and clinical research expertise; Sanford-Burnham’s fundamental research expertise and technology platforms; and Moffitt’s biospecimen bank (samples of tissue, cells, blood, etc.), data warehouse, and personalized medicine capabilities.

Obesity is not one condition: an interview with Dr. Steven Smith

by Heather Buschman, Ph.D. on October 21, 2011 at 9:28 am | 0 Comments

Full Article

Dr. Steven Smith, scientific director of the Translational Research Institute for Metabolism and Diabetes

Dr. Steven Smith is the scientific director of the Translational Research Institute for Metabolism and Diabetes, a collaboration between Sanford-Burnham and Florida Hospital. In a special presentation at Obesity 2011: The Obesity Society 29th Annual Scientific Meeting, held October 1-5 in Orlando, Fla., Dr. Smith discussed some up-and-coming anti-obesity agents, how they work, and how physicians might be able to put them to use. In his talk, he emphasized the importance of better understanding the fundamental cellular mechanisms that fuel obesity. With a greater appreciation for human metabolism, Dr. Smith explained, scientists will be able to develop new medications that focus less on appetite suppression (the target of most current weight loss drugs) and more on peripheral targets such as muscle or fat.

Building translational research

by Deborah Robison on May 26, 2011 at 3:25 pm | 1 comment

Full Article

Dr. Steven Smith and Dr. Stephen Gardell leave their marks on the new TRI building.

Dr. Steven Smith and Dr. Stephen Gardell sign the new TRI building.

The Translational Research Institute for Metabolism and Diabetes (TRI), a collaboration between Sanford-Burnham and Florida Hospital, is one step closer to opening its research facility. The 54,000 square-foot building recently reached its final height, and a special ceremony was held during which researchers gathered to sign one of the interior columns. Construction to enclose the building will now begin. The TRI, which studies diabetes, obesity and the metabolic origins of cardiovascular disease, will help bridge the gap between the scientist’s laboratory and the patient’s bedside. The TRI will unite scientists, clinicians and advanced technologies to spur translational research and rapidly create new, more effective treatments.

“We are witnessing an epidemic of obesity and diabetes in the United States,” said Dr. Steven R. Smith, scientific director of the TRI. “The main goal of the TRI is to generate new knowledge to improve lives through innovative research. By ‘topping out’ the TRI, we are one step closer towards developing Orlando as a medical destination.”

A different kind of dorm room

by Heather Buschman, Ph.D. on May 19, 2011 at 5:00 am | 3 Comments

Full Article

This calorimetry suite will be an important tool in the new Translational Research Institute facility, opening January 2012 (rendering by Flad Architects)

Calorimetry suite in the new Translational Research Institute facility, due to open January 2012 (artist's rendering by Flad Architects)

Obesity negatively affects the entire body – no organ system is left untouched. It increases a person’s risk of type 2 diabetes, high blood pressure, depression, certain cancers and many other conditions. If the current trend of expanding waistlines continues, the U.S. Centers for Disease Control and Prevention estimates that at least one in five Americans will be diabetic by the year 2050.

The goal of the Translational Research Institute for Metabolism and Diabetes (TRI), a collaboration between Florida Hospital and Sanford-Burnham, is to alter this course by translating basic scientific discoveries in the laboratory to usable information and products that improve the diagnosis and treatment of human diseases – especially obesity and diabetes.

“At the moment, there is a big gap between what we know and what we want to know about human metabolism, obesity and diabetes. Our ultimate goal in translational research is to bridge that gap,” says Dr. Steven R. Smith, TRI’s scientific director and professor at Sanford-Burnham. “As basic researchers continue to unravel the molecular underpinnings of these diseases, TRI will be conducting proof-of-concept experiments to validate new drug targets and test new therapies for safety and efficacy.”

When it opens in January 2012, the TRI’s new three-story facility in Orlando, Florida will contain a research clinic, imaging technology, a biorepository for sample collection and storage, and several other resources for metabolic studies. But the facility’s highlight will be the calorimeter rooms – small dormitory-style rooms outfitted with a bed, treadmill and toilet. These whole-room calorimeters will allow the TRI staff to measure fat and carbohydrate oxidation and energy expenditure as a person goes about his or her normal life – sleeping, eating, walking, etc. As the patient exercises on the treadmill, scientists will be able to measure his or her oxygen consumption and calories burned without using invasive tubing or sensors. This approach will provide superior comfort – and therefore generate more accurate data – during exercise.

Collaboration with Takeda seeks to translate research into treatments

by Josh Baxt on December 28, 2010 at 4:00 am | 0 Comments

Full Article

Sanford-Burnham, Florida Hospital and Takeda Pharmaceutical have formed a collaboration to investigate new therapies for obesity, a growing worldwide health problem. The partnership leverages the three organizations’ strengths in basic biomedical research, clinical research and drug development to identify obesity-related biomarkers and other targets with therapeutic potential.“There is an epidemic of obesity in the U.S.; two-thirds of Americans are now overweight or obese. These staggering statistics serve as a call for decisive action, including innovative bench-to-bedside translational research,” says Dr. Steven R. Smith, scientific director of the Florida Hospital-Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI). “This partnership with Takeda, TRI and Sanford-Burnham represents a major milestone in the quest for a better understanding of obesity as a disease and a pathway forward for the development of safe and effective therapies.”

New home for translational research

by Deborah Robison on December 14, 2010 at 1:06 pm | 2 Comments

Full Article

Dr. Steven Smith, executive director of the Florida Hospital-Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI), took control of a backhoe to help demolish an old facility on the site of TRI’s new research building. The three-story facility will unite Sanford-Burnham’s laboratory research with Florida Hospital’s patient-oriented studies to translate basic science discoveries into new treatments.

“We are witnessing an epidemic of obesity and diabetes in the United States,” said Dr. Smith. “Current statistics show that two-thirds of all Americans are overweight and obese and one in 12 has some form of diabetes. These staggering statistics call for decisive action and that includes innovative research.”

The new TRI facility will contain clinic space, testing rooms, medical imaging, a biorepository and advanced technologies to develop personalized treatments. The new facility is expected to be completed by the end of 2011.

“The TRI provides a virtual bridge between Florida Hospital’s Orlando campus and Medical City at Lake Nona,” said Dr. Daniel Kelly, scientific director at Sanford-Burnham at Lake Nona. “Instead of cars, information will speed back and forth on the bridge to accelerate discoveries leading to new treatments.”

Florida’s Bioscience Leaders Convene

by Deborah Robison on October 29, 2010 at 12:12 pm | 0 Comments

Full Article

Drs. Stephen Gardell and Stephen Vasile represented Sanford-Burnham Medical Research Institute earlier this week at the 13^th annual BioFloridaConference. The conference is the state’s largest gathering of life science professionals and a showcase for Florida’s biomedical science industry. Both Sanford-Burnham scientists shared their insights into trends and issues facing Florida’s fast-growing biomedical sector.An early session focused on integrating research and clinical practice. Dr. Gardell spoke of Sanford-Burnham’s partnership with Florida Hospital and the formation of The Florida Hospital – Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI-MD), which bridges basic research and patient-oriented research. The TRI-MD is expected to accelerate the development of new ways to diagnose, prevent, and treat diabetes and obesity and their cardiovascular complications. Dr. Gardell explained the key elements of the partnership, including Florida Hospital’s large patient base and clinical research expertise and Sanford-Burnham’s basic science prowess and advanced research technologies.

Welcome to “MeD Camp”

by Heather Buschman, Ph.D. on July 22, 2010 at 3:34 pm | 0 Comments

Full Article

Scientists at Sanford-Burnham’s Lake Nona campus recently hosted 26 high school students from surrounding Orlando schools during the second annual Medical Summer Camp (MeD Camp), a joint project with Florida Hospital that introduces students to life science careers.

Teaming up to fight obesity

by Josh Baxt on June 24, 2010 at 12:52 pm | 0 Comments

Full Article

Today’s Orlando Sentinel features a unique initiative that Florida Hospital (a Sanford-Burnham partner) has created to fight childhood obesity. Called Healthy 100 Kids, the program unites a pediatrician, a registered dietitian, a child psychologist and an exercise physiologist to help children overcome this debilitating condition. Sanford-Burnham researchers will work with the clinicians to determine the geneticcauses of obesity and which treatments work best.

“Childhood obesity is a very complex issue that requires many specialists and time and specialized resources to be able to really put a dent in it, to really make a difference for the families,” said Dr. Angela Fals, a pediatrician specializing in obesity and the lead doctor in the program.

The Translational Research Institute (TRI), a collaboration between Florida Hospital and Sanford-Burnham, will develop a biorepository and clinical research database to further explore childhood obesity. Sanford-Burnham will use this data to identify genes that lead to obesity and diabetes.

“We’re interested in factors that influence susceptibility,” said Dr. Steven Smith, executive director of the TRI and Sanford-Burnham faculty member. “We need to understand why some kids are more susceptible than others to becoming obese.”

Check out the article: New Florida Hospital program tackles childhood obesity with unique approach.

Joining forces with the International Prostate Cancer Foundation to develop better tests

Partnering with Asia’s largest pharmaceutical company to find obesity treatments

How belly fat differs from thigh fat—and why it matters

Top 10 most-read blog posts of 2012: #9

Translational Research Institute establishes new research paradigm for metabolic diseases

A “twisted” grand opening ceremony

Translational Research Institute establishes new research paradigm for metabolic diseases

Introducing the Partnership for Personalized Medicine in Florida

Obesity is not one condition: an interview with Dr. Steven Smith

Building translational research

A different kind of dorm room

Collaboration with Takeda seeks to translate research into treatments

New home for translational research

Florida’s Bioscience Leaders Convene

Welcome to “MeD Camp”

Teaming up to fight obesity

Search

Find more information

Please take a quick survey

Which of these items describes you?

Categories

Translational Research Institute establishes new research paradigm for metabolic diseases

Search

Find more information

Please take a quick survey

Which of these items describes you?

Categories

Search by Keyword